Treatment with either Dox or Tam led to dramatic tumor-specific reductions in the Ki-67 cellular proliferation marker, Dox-specific loss of MYCN expression, or Tam-specific induction of the p53 target Cdkn1a (Figures 3F–3H; Figure S3G). This evidence concerns the gene TP53 and neoplasm.